NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

Mammoth Biosciences

Business Name: Mammoth Biosciences
Business Genre:
Business Description:

San Francisco-based company that uses CRISPR-Cas9 tech to “address challenges across healthcare, agriculture, environmental monitoring, biodefense, and more”. Team includes Jennifer Doudna, co-inventor of CRISPR-Cas genome editing [4]

City: San Francisco
State: CA
Country: USA
Data/Evidence of Effectiveness: 95% positive predictive agreement and 100% negative predictive agreement. LOD is 10 copies/uL. Does not cross react with other respiratory viruses. [3]
Complimentary Products Needed to Perform Test: Kit not commercialized yet. [3]
Setting of Care: Not authorized, but likely authorized setting H [3]
Current Status / Clinical Development Stage / Expected Milestones: Awaiting EUA approval [2]
Funding & Ownership : privately owned by investors, mix of companies and individuals listed on website [4]
Business Model: don’t seem to produce or sell any physical materials, possibly sell IP [4]
IP: paper is copyrighted to publisher, DETECTR system is proprietary [3] [2]
History & Origins : Company focuses on development of CRISPR-cas tech for diagnostics, genome editing, and protein discovery, DETECTR platform can detect other infectious diseases [4] [5]
Date EUA Issued: Currently under review [1] [2]
Sources: [1] https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd [2] https://www.webwire.com/ViewPressRel.asp?aId=259386 [3] https://www.nature.com/articles/s41587-020-0513-4 [4] https://mammoth.bio/about/ [5] https://mammoth.bio/diagnostics/
Organization: CEO: Trevor Martin. CTO: Janice Chen. CSO: Lucas Harrington. Chair of Scientific Advisory Board: Jennifer Doudna. Chief Busines Officer: Peter Nell. Legal Counsel: William Smith. Chief Operations Officer: Ted Tisch [4]
Time to Result: 40 minute runtime after RNA extraction and prep [3]
Test Sample Type: nasopharyngeal swab, oropharyngeal swab [3]
Technology Overview: CRISPR-cas12 holds piece of target DNA and finds match in solution, and cuts DNA at site. Then cutting is ‘active’ and continues to cut fluorescent probes away from quenchers that are also in solution. Targets the E and N genes. [3]
Testing Type: CRISPER-cas12 lateral flow with RT-LAMP [3]
Test Category: CRISPR
Test Name: DETECTR [2] [3]
Clinical Application & Need: detect current infection from respiratory swab RNA extracts [3]

Send Message to listing owner